FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Miami, FL, March 14, 2018 -- Curative Biosciences, Inc., (OTCBB: CBDX) ("Curative") is pleased to announce that the Financial Industry Regulatory Authority (FINRA) has assigned “CBDX” as the Company's new ticker symbol and it has commenced trading under that symbol today.
For information on Curative and the Company’s portfolio of Hemp CBD oil products please visit www.curativebiosciences.com.
Investor relations information is available by emailing [email protected] or by calling (949) 287-3164.
About Curative Biosciences, Inc.
Curative Biosciences (CBDX), is creating a new category in the health industry by translating advances in science and technology into effective, scientifically sound health products available to people in their everyday lives. We are developing a portfolio of products with compelling compounds found in nature that offer an opportunity for our customers to proactively support their health.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available at the website maintained by the SEC at http://www.sec.gov.
Contact: www.curativebiosciences.com [email protected] (949) 287-3164
